Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Cabozantinib, and Ipilimumab in Advanced Non-Squamous NSCLC
NCT03468985Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2018
- Primary completion
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib, ipilimumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by National Cancer Institute. Started May 2018; status: completed.
02
Drugs
cabozantinibipilimumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03468985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468985.